TIAA CREF Investment Management LLC held its stake in shares of Entellus Medical, Inc. (NASDAQ:ENTL) during the first quarter, according to its most recent filing with the SEC. The fund owned 20,577 shares of the medical technology company’s stock at the end of the first quarter. TIAA CREF Investment Management LLC owned 0.10% of Entellus Medical worth $284,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Parametric Portfolio Associates LLC raised its stake in shares of Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after buying an additional 573 shares during the last quarter. Swiss National Bank increased its position in shares of Entellus Medical by 98.9% in the first quarter. Swiss National Bank now owns 17,700 shares of the medical technology company’s stock valued at $244,000 after buying an additional 8,800 shares during the last quarter. TD Asset Management Inc. acquired a new position in shares of Entellus Medical during the first quarter valued at about $279,000. Keybank National Association OH increased its position in shares of Entellus Medical by 19.2% in the first quarter. Keybank National Association OH now owns 29,359 shares of the medical technology company’s stock valued at $405,000 after buying an additional 4,721 shares during the last quarter. Finally, Eqis Capital Management Inc. increased its position in shares of Entellus Medical by 22.8% in the first quarter. Eqis Capital Management Inc. now owns 33,475 shares of the medical technology company’s stock valued at $462,000 after buying an additional 6,223 shares during the last quarter. 70.41% of the stock is currently owned by institutional investors.

Shares of Entellus Medical, Inc. (NASDAQ ENTL) traded up 0.52% on Wednesday, reaching $17.55. The company had a trading volume of 67,143 shares. The stock’s market cap is $445.26 million. The stock has a 50-day moving average price of $17.23 and a 200-day moving average price of $14.98. Entellus Medical, Inc. has a 12 month low of $11.47 and a 12 month high of $22.63.

Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The company had revenue of $22.10 million during the quarter, compared to analysts’ expectations of $21.87 million. During the same quarter in the prior year, the business posted ($0.27) EPS. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. Analysts predict that Entellus Medical, Inc. will post ($1.61) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “TIAA CREF Investment Management LLC Holds Position in Entellus Medical, Inc. (ENTL)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/30/tiaa-cref-investment-management-llc-holds-position-in-entellus-medical-inc-entl.html.

A number of research firms have recently weighed in on ENTL. ValuEngine downgraded Entellus Medical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 23rd. BidaskClub downgraded Entellus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 8th. Piper Jaffray Companies restated a “buy” rating and set a $21.00 target price on shares of Entellus Medical in a research report on Tuesday, August 22nd. Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Finally, Canaccord Genuity downgraded Entellus Medical from a “buy” rating to a “hold” rating and dropped their target price for the stock from $22.00 to $18.00 in a research report on Thursday, May 4th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $21.71.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.